866-997-4948(US-Canada Toll Free)

Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 26 Pages

Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H2 2017

Summary

Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report Phenylalanine 4 Hydroxylase - Pipeline Review, H2 2017, outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Phenylalanine 4 hydroxylase or Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate tyrosine. The enzyme works with a molecule called tetrahydrobiopterin (BH4) to carry out this chemical reaction. Tyrosine is used to make several types of hormones, certain chemicals that transmit signals in the brain (neurotransmitters), and a pigment called melanin, which gives hair and skin their color. The molecules developed by companies in Preclinical stages are 5 respectively. Report covers products from therapy areas Metabolic Disorders which include indications Phenylketonuria (PKU) and Phenylalanine Hydroxylase Deficiencies.

Furthermore, this report also reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)
- The report reviews Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Overview 5
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Therapeutics Development 6
Products under Development by Stage of Development 6
Products under Development by Therapy Area 7
Products under Development by Indication 8
Products under Development by Companies 9
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Therapeutics Assessment 11
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 14
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Companies Involved in Therapeutics Development 16
Codexis Inc 16
Synthetic Biologics Inc 16
Ultragenyx Pharmaceutical Inc 16
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Drug Profiles 18
CDX-6114 - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
DTX-501 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
Gene Therapy to Activate PAH for Phenylalanine Hydroxylase Deficiencies - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Small Molecules to Activate Phenylalanine Hydroxylase for Phenylketonuria - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
SYN-200 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Dormant Products 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 25
Disclaimer 26

List of Tables
Number of Products under Development by Stage of Development, H2 2017 6
Number of Products under Development by Therapy Areas, H2 2017 7
Number of Products under Development by Indication, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Products under Development by Companies, H2 2017 10
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 13
Number of Products by Stage and Molecule Type, H2 2017 15
Pipeline by Codexis Inc, H2 2017 16
Pipeline by Synthetic Biologics Inc, H2 2017 16
Pipeline by Ultragenyx Pharmaceutical Inc, H2 2017 17
Dormant Projects, H2 2017 24

List of Figures
Number of Products under Development by Indications, H2 2017 8
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Molecule Types, H2 2017 14
Number of Products by Stage and Molecule Types, H2 2017 14

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *